Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data

Bausch and Brent Saunders mutually agreed on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.